Phase I study of FOLFOXIRI+Cmab in patients with KRAS wild-type unresectable colorectal cancer
Phase 1
- Conditions
- Colorectal cancer
- Registration Number
- JPRN-UMIN000013711
- Lead Sponsor
- Kobe City Medical Center General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1) active synchronous or metachronous malignancy other than carcinoma in situ 2) pregnant or nursing 3) severe mental disorders 4) systemic steroid user 5) diabetes mellitus, uncontrolled 6) history of myocardial infarction, unstable angina within 3 months prior to the registration 7) serious coexisting illness 8) active infection 9) peripheral neuropathy greater than Grade 2 10) ileus 11) massive pleural effusion,ascites 12) history for allergy of L-OHP,CPT-11,5-FU,L-LV,bevacizumab 13) Receiving Atazanavir 14) KRAS mutant-type
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method